Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own

For Campus Prearrival Information <click here>
For a PDF of the 2015 Program Materials <click here>
For ALL Abstracts [1-220] in sequential order <click here>
For ALL Authors of the Lecture and Poster Presentations <click here>


View analytic
Tuesday, August 25 • 2:40pm - 3:20pm
[0104] Elucidation of the Structure and Stereochemistry of the Metabolites of the HCV Protease Inhibitor Faldaprevir

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Faldaprevir is an HCV Protease Inhibitor for the treatment of Hepatitis C infection.  The first small molecule treatment for HCV, the macrocycle BILN 2061, was the predecessor of Faldaprevir. Human clinical isolates following administration of Faldaprevir were found to contain four major human metabolites.  Elucidation of the structure of each of these metabolites was achieved through a combination of isotopic labelling, LC-NMR, HPLC-MS, global esterification/chromatography and total synthesis.  Implications for the molecular-level inetractions of the drug in the Cyp-3A4 active site will also be discussed.


Invited Lecturers
avatar for Carl Busacca

Carl Busacca

Distinguished Research Fellow, Boehringer Ingelheim
Boehringer Ingelheim | November 1994 – Present (20 years 4 months) | | Chemist | Sterling Winthrop | January 1990 – November 1994 (4 years 11 months) | Rensselaer, NY | | Colorado State University | Doctor of Philosophy (Ph.D.), Organic Chemistry | 1985 – 1989


Tuesday August 25, 2015 2:40pm - 3:20pm
MCC Theater